In this prognostic study of 190 patients with RM-NPC receiving anti–PD-1 monotherapy, baseline plasma EBV DNA titers and their dynamics were significantly associated with progression-free survival, overall survival, and durable clinical benefit (defined as progression-free survival of ≥6 months). Here, PDCD1 is linked to nasopharyngeal carcinoma.